Evolus
EOLS
172 hedge funds and large institutions have $539M invested in Evolus in 2025 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 64 increasing their positions, 50 reducing their positions, and 34 closing their positions.
1,954% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $587K
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
5.4% more ownership
Funds ownership: 85.34% → 90.74% (+5.4%)
4% less funds holding
Funds holding: 179 → 172 (-7)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
17% less capital invested
Capital invested by funds: $653M → $539M (-$114M)
18% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$24.9M |
| 2 |
EP
Eversept Partners
New York
|
+$12M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.6M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$9.38M |
| 5 |
PA
Pinnacle Associates
New York
|
+$7.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$16.9M |
| 2 |
SFM
Soros Fund Management
New York
|
-$12M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
-$8.67M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.42M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.66M |
EOLS Hedge Fund Activity: Q2 2025 in Review
172 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Evolus (EOLS) for Q2 2025, worth a combined $539M — down 17% from $653M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of EOLS and 28 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 64 added.
The largest buyer was Frazier Life Sciences Management, opening a new position worth an estimated $24.9M. The largest seller was Perceptive Advisors, cutting an estimated $16.9M.
- 172 institutional investors held Evolus (EOLS) as of Q2 2025, down from 179 in Q1 2025.
- Funds reported $539M of Evolus stock for Q2 2025, down 17% quarter-over-quarter.
- 28 funds opened new Evolus positions in Q2 2025 and 34 closed out, a net change of -6 holders.
- The largest Evolus buyer in Q2 2025 was Frazier Life Sciences Management, an estimated $24.9M added.
- The largest Evolus seller in Q2 2025 was Perceptive Advisors, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2025.